Cerenis Therapeutics, Inc. Reports Two Positive Phase II Studies For HDL Mimetic CER-001 At EAS
6/2/2014 9:09:13 AM
TOULOUSE, France & ANN ARBOR, Mich.--(BUSINESS WIRE)--Cerenis Therapeutics, the biopharmaceutical company, today announced that two of its Phase II studies, SAMBA and MODE (Modifying Orphan Disease Evaluation), with CER-001, an engineered human apoA-I-containing pre-ß HDL mimetic, met their primary clinical endpoints in patients with Familial Primary Hypoalphalipoproteinemia (FPHA) and Homozygous Familial Hypercholesterolemia (HoFH), respectively.
Help employers find you! Check out all the jobs and post your resume.
comments powered by